Differential regulation of neuropeptide mRNA expression in intrastriatal striatal transplants by host dopaminergic afferents.
The effects of dopamine-specific manipulations on neuropeptide gene expression in intrastriatal grafts of fetal striatal tissue were studied by quantitative in situ hybridization histochemistry, using 35S-labeled oligonucleotide probes. Messenger RNA transcripts for the striatal neuropeptides preproenkephalin (PPE) and preprotachykinin (PPT) were detected in neurons forming discrete patches in the striatal grafts. The relative abundance of PPE and PPT mRNA-expressing neurons within the graft patches (51-54%) was similar to that found in normal caudate-putamen. In specimens with intact dopamine afferents the expression of PPE mRNA in grafted neurons was similar to that found in normal caudate putamen, whereas the hybridization signal for PPT mRNA was 27% higher in the graft neurons than in the normal caudate-putamen. Removal of host dopaminergic afferents by 6-hydroxydopamine lesions of the ipsilateral mesostriatal dopamine pathway increased the hybridization signal for PPE mRNA both in the grafts (+84%) and in the spared ipsilateral host caudate-putamen (+125%), whereas the PPT signal was reduced by 53% in the grafts and by 51% in the remaining host caudate-putamen. Similarly, chronic treatment of grafted animals with the dopamine receptor antagonist haloperidol (2 mg/kg per day for 10 days) produced a 146% increase in the PPE signal in the grafts and a 175% increase in the intact contralateral caudate-putamen, whereas the signal for PPT mRNA was again decreased by 52% and 51% in the grafts and host caudate-putamen, respectively. These results show that the host nigrostriatal dopamine pathway differentially regulates enkephalin and substance P gene expression within striatal grafts and thereby exerts a tonic functional influence over grafted striatal neurons.
Campbell
K
K
Department of Medical Cell Research, University of Lund, Sweden.
Wictorin
K
K
Björklund
A
A
D000344:Afferent Pathways / Q000502:physiology*; D000818:Animals; D001345:Autoradiography; D016380:Brain Tissue Transplantation / Q000502:physiology*; D002421:Caudate Nucleus / Q000187:drug effects / Q000502:physiology; D003342:Corpus Striatum / Q000187:drug effects / Q000502:physiology* / Q000637:transplantation*; D004298:Dopamine / Q000502:physiology*; D004745:Enkephalins / Q000096:biosynthesis / Q000235:genetics*; D005260:Female; D016332:Fetal Tissue Transplantation / Q000502:physiology; D005786:Gene Expression Regulation; D006220:Haloperidol / Q000494:pharmacology; D017403:In Situ Hybridization; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology; D015345:Oligonucleotide Probes; D016627:Oxidopamine; D011498:Protein Precursors / Q000096:biosynthesis / Q000235:genetics*; D011699:Putamen / Q000187:drug effects / Q000502:physiology; D012333:RNA, Messenger / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013462:Sulfur Radioisotopes; D015320:Tachykinins / Q000096:biosynthesis / Q000235:genetics*
D004745:Enkephalins; D015345:Oligonucleotide Probes; D011498:Protein Precursors; D012333:RNA, Messenger; D013462:Sulfur Radioisotopes; D015320:Tachykinins; C044206:preprotachykinin; D016627:Oxidopamine; C033660:preproenkephalin; D006220:Haloperidol; D004298:Dopamine